A Therapeutic Regimen Using Neoantigen-Specific TCR-T Cells for HLA-A*2402-Positive Solid Tumors

Scientists identified a functional TCR, Tcr-1, which selectively recognized the SYT-SSX fusion neoantigen shared by most synovial sarcomas.